EUVIMEDEUVIMED entdecken
Crossref

Hormone Refractory Prostate Cancer: Focus on Sipuleucel-T

Christian Doehn, Martin Sommerauer, Xiyuan Guo, Ingo Kausch, Dieter Jocham

Clinical Medicine. Therapeutics · 2009

DOI: 10.4137/cmt.s1084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Medicine. Therapeutics, 2009. Verfasst von Christian Doehn und 4 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sipuleucel-T is a vaccine based on autologous antigen presenting cells that are loaded with an antigen-cytokine (prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor) fusion product. Sipuleucel-T is given intravenous in weeks 0, 2, and 4. Within phase I–III trials, patients with metastatic hormone-refractory prostate cancer have been treated. In these trials an activation of the immune system could be demonstrated. Also, some clinical responses could be documented. Moreover, in a placebo-controlled phase III trial including 127 patients a statistical significantly prolongation of survival was achieved. Side effects from the vaccine are rather mild and included fever, myalgia, fatigue and others. The Food and Drug Administration in the United States requested further data before possible approval of sipuleucel-T.

Zitieren

APA

Doehn, C., Sommerauer, M., Guo, X., Kausch, I., & Jocham, D. (2009). Hormone Refractory Prostate Cancer: Focus on Sipuleucel-T. Clinical Medicine. Therapeutics. https://doi.org/10.4137/cmt.s1084

Vancouver

Doehn C, Sommerauer M, Guo X, Kausch I, Jocham D. Hormone Refractory Prostate Cancer: Focus on Sipuleucel-T. Clinical Medicine. Therapeutics. 2009. doi:10.4137/cmt.s1084

BibTeX
@article{Doehn2009,
  author = {Doehn, Christian and Sommerauer, Martin and Guo, Xiyuan and Kausch, Ingo and Jocham, Dieter},
  title = {Hormone Refractory Prostate Cancer: Focus on Sipuleucel-T},
  journal = {Clinical Medicine. Therapeutics},
  year = {2009},
  doi = {10.4137/cmt.s1084}
}
Kostenlos starten →